Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Topical Insulin Therapy for Persistent Corneal Epithelial Defects

15. November 2026 aktualisiert von: Reza Dana, MD, Massachusetts Eye and Ear Infirmary

The goal of this clinical trial is to learn if insulin eye drops, added to standard care, can treat persistent corneal epithelial defects (PEDs) in adults age 18 and older. A PED is a corneal surface wound, at least 2 mm across, that has not healed after more than 14 days of standard treatment such as lubricants, antibiotic drops, or a bandage contact lens. The main question it aims to answer is:

- Does adding insulin eye drops (1 IU/mL, four times daily) to standard care increase the proportion of eyes with complete corneal epithelial healing at 8 weeks?

The standard care plus insulin eye drops will be compared to standard care plus placebo eye drops (preservative-free saline) to see if insulin leads to more complete healing, faster healing, fewer recurrences, and better symptom relief. They will also assess the safety of the drops and their effects on corneal nerves.

Participants will:

  • Be randomly assigned (1:1) to insulin or placebo drops. Neither participants nor the investigators assessing healing will know which drops are used. The study is single-center (Massachusetts Eye and Ear) and plans to enroll 40 participants, one eye each.
  • Use the study drops four times daily for up to 8 weeks, along with standard care chosen by their cornea specialist, and return weekly for a fresh, refrigerated supply.
  • Attend study visits at baseline and at weeks 1, 4, 8, and 12 for visual acuity testing, slit-lamp examination, fluorescein staining and photography of the defect, and imaging of corneal nerves (in vivo confocal microscopy).
  • Complete symptom questionnaires (pain, foreign body sensation, light sensitivity) at baseline and week 8, and have corneal sensation tested before and after treatment.
  • Have blood glucose monitored if they have diabetes.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Corneal diseases are a leading cause of blindness worldwide according to the World Health Organization; many are in need of a corneal transplant but with a dearth of available tissue and proper medical/surgical expertise and care, the vast majority remain blind. A common cause of corneal blindness is untreated corneal epithelial defects. And as we explain below, the treatment options are very limited.

A persistent corneal epithelial defect (PED) is defined as a failure of the cornea to re-epithelialize within 2 weeks with standard treatment, and is caused by many underlying reasons, including nerve damage (e.g. in diabetes or herpetic infection), trauma, limbal stem cell deficiency, and severe inflammation of the ocular surface, among others. As PEDs are often refractory to conventional therapy (such as lubrication, bandage contact lenses, punctal occlusion, or surgical lid closure), they can progress to serious sequalae such as stromal ulceration, scarring, and even perforation. In particular, corneal scarring is a leading cause of blindness and visual disability, especially in regions with limited access to corneal transplantation. These risks underscore the need for improved and affordable treatments effective in promoting corneal epithelial healing, thereby limiting irreversible scarring and corneal opacity.

Rationale for Topical Insulin Therapy: Insulin is widely known as a metabolic hormone, but it also has growth-factor-like actions in various tissues, including the cornea. Importantly, insulin is widely available worldwide and can easily be compounded into eyedrops for use. The following preliminary evidence supports the use of topical insulin eye drops to promote corneal epithelial defect healing:

  1. Cell Growth (Trophic) Effects: Insulin can stimulate proliferation and migration of epithelial cells, essential for wound closure. At the ocular surface, exogenous insulin has been shown to stimulate corneal epithelial cell proliferation and migration, as well as the production of other growth factors involved in tissue regeneration. In preclinical studies, topical insulin significantly accelerated corneal epithelial wound healing. A recent study in diabetic mice demonstrated that insulin eye drops markedly promoted corneal re-epithelization and concurrently reduced corneal inflammatory responses vs. untreated controls.
  2. Ease of Preparation and Cost: Insulin eye drops are simple to prepare and inexpensive. Pharmacy compounding of topical insulin involves diluting readily available injectable human insulin into sterile saline or artificial tear solution to the desired concentration (1 IU/mL for topical administration).13,14
  3. No special storage or complex delivery devices are needed beyond standard dropper bottles. The simplicity of this formulation allows the wide availability of the therapy (even in resource-limited settings) at a fraction of the cost of biologics like Cenegermin.
  4. Preliminary Clinical Evidence: A growing number of case reports and small series have documented successful corneal healing with topical insulin. A small pilot study in 2024 treated patients with refractory PEDs using insulin eye drops as an adjunct to conventional therapy. The results were encouraging: 16 out of 23 patients (≈70%) showed complete healing or marked improvement in their epithelial defect, typically within 4-8 weeks of starting insulin therapy. Importantly, there were no significant adverse effects reported with topical insulin in this study. Wang et al. reported a series of 6 severe neurotrophic corneal ulcer patients (mix of diabetic and non-diabetic) in which all six achieved complete re-epithelialization on insulin drops within 1-4 weeks.
  5. Anti-Inflammatory Effects: Beyond simply "filling the gap" for NGF-nonresponsive patients, insulin might confer additional therapeutic benefits. Emerging evidence indicates that insulin has anti-inflammatory properties in the cornea. By binding insulin receptors on corneal and immune cells, it can modulate cytokine release and reduce the level of inflammatory biomarkers during wound healing.
  6. Insulin may promote corneal nerve regeneration, as increased corneal nerve fiber density and higher levels of neuropeptides (substance P and CGRP) in insulin-treated corneas, suggesting a restorative effect on the corneal innervation.

Knowledge Gaps and Unmet Need: Despite the scientific rationale and early reports cited above, critical gaps remain in our knowledge that must be addressed before insulin eye drops can be adopted as a standard treatment for corneal healing:

  • Lack of Rigorous Clinical Trials: To date, no sizeable randomized controlled trial (RCT) has been completed to definitively establish the efficacy of topical insulin for PEDs. The evidence for insulin's benefit comes from case series, small uncontrolled studies, or trials in very specific scenarios. A well-powered RCT is needed to provide high-quality evidence of efficacy and safety in a broader PED population.

  • Optimal Dosing and Treatment Regimen: There is no consensus on the effective dose, frequency, or duration of topical insulin for PEDs. Different studies have reported concentrations ranging from 0.5 U/mL up to 10 U/mL, with dosing frequencies between 4 and 6 times a day, and treatment courses from a few days to several weeks.17,21 Thus, standardizing the regimen is critical for reproducibility and regulatory approval.

  • Mechanistic Insights: While insulin's general effects on limbal stem cells are known, the precise mechanisms by which topical insulin promotes corneal epithelial defect closure are still being elucidated. A deeper understanding of the mechanism could help in optimizing combination therapies.

    2. Specific Aims and Objectives

The primary objective is to determine whether adjunctive topical insulin (1 IU/mL, four times a day) increases the proportion of PED patients achieving complete corneal healing within 8 weeks, compared to placebo (saline) controls, under double masked conditions.

The secondary objective is to (1) compare time to defect healing vs. without insulin therapy; (2) to assess the durability of healing (rate of recurrence of defects after initial healing); (3) assess patient symptom improvements (pain) with insulin; (4) document safety issues or side effects of topical insulin on the eye; (5) to explore changes in corneal nerve density and sensitivity in insulin-treated eyes.

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Frühphase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

  • Name: Rohan B Singh, MD
  • Telefonnummer: 234-980-0015

Studienorte

    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts Eye and Ear

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults age 18 and older.
  • 2. Focal corneal epithelial defect (≥ 2mm in longest dimension) present for > 14 days despite standard treatment (e.g. lubrication, antibiotic, bandage contact lens, etc.)

Exclusion Criteria:

  • Active uncontrolled infection in the study eye.
  • Impending corneal perforation (that requires urgent surgery).
  • Other ocular comorbidities that would confound healing.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Control

All control patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.

All patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.

Aktiver Komparator: Treatment

In the insulin arm, patients will receive topical regular human insulin diluted to 1 IU/mL in sterile preservative-free normal saline, applied as an eye drop four times a day (QID).

The patients will receive topical regular human insulin diluted to 1 IU/mL in sterile preservative-free normal saline, applied as an eye drop four times a day (QID). Additionally, all interventional arm patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Complete PED closure rate at 8 Weeks
Zeitfenster: 8 weeks

The primary endpoint is the proportion of eyes in each group that achieve complete corneal epithelial defect closure by 8 weeks of treatment. "Complete healing" is defined as 100% re-epithelialization of the cornea with no fluorescein staining defect remaining, confirmed on two consecutive visits including the final 8-week visit. We will document epithelial closure using fluorescein staining and slit-lamp photography at each follow-up. An independent masked ophthalmologist will review images to confirm healing status, using standardized criteria.

8 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to Healing
Zeitfenster: 8 weeks

For each eye that heals during the study, we will record the number of days from treatment initiation to the first visit at which the defect is fully closed. We hypothesize the insulin group will have a faster time-to-healing (accelerated re-epithelialization) compared to controls. We will use survival analysis methods (Kaplan-Meier curves and log-rank test) to compare time-to-healing distributions.

8 weeks
Partial Healing (Defect Reduction)
Zeitfenster: 8 weeks

In eyes that do not completely heal, we will assess the change in defect size. Specifically, the percentage reduction in defect area from baseline to 8 weeks (measured from corneal staining photographs) will be calculated. We will compare the mean reduction and the proportion of eyes achieving at least a 50% reduction in area between groups. This will capture any clinically meaningful improvement short of full closure.

8 weeks
Recurrence Rate
Zeitfenster: From documented complete epithelial healing through 12 weeks after completion of the 8-week treatment period.

Recurrence is defined as the development of a new corneal epithelial defect greater than 1 mm in diameter at the same anatomical location following documented complete epithelial healing. The outcome will be reported as the percentage of participants who experience at least one recurrence during the 12-week follow-up period after completion of the 8-week treatment phase, among participants whose epithelial defects healed during treatment.

From documented complete epithelial healing through 12 weeks after completion of the 8-week treatment period.
Symptom Relief
Zeitfenster: 8 weeks

Ocular surface symptoms and their impact on vision-related functioning will be measured using the validated 12-item Ocular Surface Disease Index (OSDI) questionnaire at baseline and Week 8. The OSDI total score ranges from 0 to 100, with higher scores indicating greater symptom severity and functional impairment. The outcome will be reported as the change in total OSDI score from baseline to Week 8, calculated as the Week 8 score minus the baseline score. Negative values indicate improvement in symptoms.

8 weeks
Safety Outcomes
Zeitfenster: 8 weeks

The number of participants experiencing at least one adverse event during the 8-week treatment period will be recorded and reported for each treatment group. Adverse events will include ocular and systemic events, including ocular surface inflammation, corneal edema, corneal haze, ocular infection, and systemic adverse events potentially associated with treatment. Each participant experiencing one or more adverse events will be counted once for this outcome.

8 weeks
Corneal Sub-Basal Nerve Fiber Density
Zeitfenster: 8 weeks

Corneal sub-basal nerve fiber length density will be quantified using in vivo confocal microscopy (IVCM) at baseline and at all scheduled post-treatment follow-up visits. Nerve fiber length density will be expressed as the total length of visible sub-basal corneal nerve fibers per unit area of corneal tissue (mm/mm²). The outcome will be reported as the change in nerve fiber length density from baseline at each follow-up visit, calculated as the value at the respective follow-up visit minus the baseline value. Positive values indicate an increase in corneal nerve fiber length density.

8 weeks
Corneal Sensitivity
Zeitfenster: 8 weeks

Corneal sensitivity will be measured using a Cochet-Bonnet esthesiometer at baseline and at all scheduled post-treatment follow-up visits. Corneal sensitivity will be quantified as the maximum nylon filament length, expressed in centimeters (cm), that elicits a reproducible corneal sensation or blink response. The outcome will be reported as the change in filament length from baseline at each follow-up visit, calculated as the value at the respective follow-up visit minus the baseline value. Positive values indicate improved corneal sensitivity.

8 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienstuhl: Reza Dana, MD, MSc, MPH, Massachusetts Eye and Ear, Harvard Medical School

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. November 2027

Studienabschluss (Geschätzt)

1. Januar 2028

Studienanmeldedaten

Zuerst eingereicht

9. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 2026P002049

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

IPD-Sharing-Zeitrahmen

The IPD will be available from December 1 till the study is concluded.

IPD-Sharing-Zugriffskriterien

The IPD will be available on request from Mr. Michael Cheung, Clinical Research Project Manager.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .